The FDA granted approval for Papzimeos, a drug developed by Precigen, Inc.
4 reports, 4 independent
Updated Aug 25
Gone quiet
Reached 4 outlets in its first 24 hours
- Reports
- 4
- Developments
- 1
- Repetition
- 75%
New informationRepeats or wire copies
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
The FDA granted approval for Papzimeos, a drug developed by Precigen, Inc.
Who's involved
What this event is mainly aboutKeep exploring
The entities involved
- FDA
-
Precigen, Inc
company in Blacksburg, United States
Nothing else this week.
Related events
- FDA and Pfizer are seeking regulatory approval for their products.
- FDA approval enables commercial opportunity involving CBRE Group.
- Amylyx Pharmaceuticals is seeking FDA approval for a new drug treatment.
- Unregulated products are bypassing official government approval processes.
- A study protocol involving a company based in Mont-Saint-Guibert was approved by the U.S. FDA.
Coverage
Newest first; wire copies grouped- ZacksPGEN Stock Surges 144% in August on FDA Nod for Rare Lung Disease Drug Shares of Precigen, Inc. PGEN have skyrocketed 144.4% in August so far, following the company's announcement of the FDA approval
- Insider MonkeyPrecigen (PGEN) Secures FDA Approval for Papillomatosis Treatment Precigen, Inc. (NASDAQ:PGEN) is one of the best multibagger penny stocks to buy according to analysts. On August 15, the stock explod
- BioPharma DivePrecigen wins immunotherapy approval; Pfizer sickle cell drug fails trial This story was originally published on BioPharma Dive. To receive daily news and insights, subscribe to our free daily BioPha
- PR NewswirePrecigen Announces Full FDA Approval of PAPZIMEOS (zopapogene imadenovec-drba), the First and Only Approved Therapy for the Treatment of Adults with Recurrent Respiratory Papillomatosis PAPZIMEOS app